RecruitingNCT06805552

Sarcopenia and Systemic Therapy in HCC

Prognostic Model of Survival of Patients With Hepatocarcinoma and Sarcopenia Treated With Systemic Therapy

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

270 participants

Start Date

Oct 19, 2022

Study Type

OBSERVATIONAL

Conditions

HCC - Hepatocellular Carcinoma

Summary

This is a multi-center, retrospective observational study in patients with liver cancer (HCC) to assess the impact of sarcopenia (muscle loss) on the prognosis, duration, and tolerance of systemic treatment.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

Patients aged ≥18 years.
Diagnosis of hepatocellular carcinoma based on histological and/or radiological results as defined by the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD). The staging of hepatocellular carcinoma was obtained through contrast-enhanced liver CT and/or MRI.
Patients with advanced (BCLC-C) or intermediate (BCLC-B) stage hepatocellular carcinoma, or patients with early-stage (BCLC-A) hepatocellular carcinoma who have not responded to previous locoregional ablative treatments and/or liver resection.
Treatment with TKIs according to the indications and prescription criteria defined by AIFA, with no requirement to reach a minimum treatment period.
Availability of a CT scan performed within no more than 8 weeks prior to the start of TKI therapy.
\- Obtaining written informed consent.